Clinical Trial

Sintilimab Monotherapy in Patients With Stage I-II MSI-H/dMMR Endometrial Cancer

Name: Sintilimab Monotherapy in Patients With Stage I-II MSI-H/dMMR Endometrial Cancer — clinical trial record (NCT07731607)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

To investigate the efficacy and safety of immune checkpoint inhibitors as a non-surgical (surgery-avoiding) treatment in patients with stage I-II MSI-H/dMMR endometrial cancer.

Trial Details

NCT Number	NCT07731607
Lead Sponsor	Wang Jianliu Collaborators: Innovent Biologics (Suzhou) Co. Ltd.
Conditions	MMRd Endometrial Cancer of Stage I~II
Enrollment	48 participants
Start Date	2026-07-20
Primary Completion	2030-07-20 (estimated)
Study Completion	2030-07-20 (estimated)
Updated on ClinicalTrials.gov	2026-07-28